Psilocybin is the major psychoactive compound present in magic mushrooms. Much like cannabis, psilocybin is classified as a Schedule 1 controlled substance with no medical purpose. However, recent studies have identified important medical effects of psilocybin. One area where psilocybin has been purported to affect is in the treatment of depression. The beneficial compound has been approved on two occasions for trials regarding depression by the FDA. The first trial for the compound was for severe treatment-resistant depression. The second approval was directed towards major depressive disorder. Major depressive disorder is a very common condition with over 300 million suffering from the condition.
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…
Ten p.m. on a Glendale balcony, two floors above the theater that just screened the…
We analyzed seven different 2026 rankings to find the true top 10 cannabis strains in…
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…